WEB Second Phase 2 trial initiated from BioNTech's proprietary individualized mRNA-based cancer vaccine platform.

WEB MAINZ Germany October 19 2023 GLOBE NEWSWIRE BioNTech SE Nasdaq

WEB July 30 Reuters - COVID-19 vaccine maker BioNTech's 22UAyDE cancer drug candidate BNT111 showed

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine.

Der Impfstoffhersteller Biontech will mRNA-basierte Krebsimpfstoffe entwickeln die das Immunsystem.

Wie Biontech am Dienstag mitteilte zeigte eine Kombinationstherapie aus genetisch veränderten Immunzellen.